SEC Form SC 13D filed by GlycoMimetics Inc.

$GLYC
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $GLYC alert in real time by email
SC 13D 1 p24-3168sc13d.htm GLYCOMIMETICS INC

 

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
   
SCHEDULE 13D
 
Under the Securities Exchange Act of 1934
(Amendment No. )*
 

GlycoMimetics, Inc.

(Name of Issuer)
 

Common Stock, par value $0.001 per share

(Title of Class of Securities)
 

38000Q102

(CUSIP Number)
 
Robert Atchinson
Adage Capital Partners GP, L.L.C.
200 Clarendon Street, 52nd Floor
Boston, MA 02116

(617) 867-2800

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
 

October 29, 2024

(Date of Event Which Requires Filing of This Statement)
 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

 

(Page 1 of 11 Pages)

______________________________

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 38000Q102SCHEDULE 13DPage 2 of 11 Pages

 

1

NAME OF REPORTING PERSON

Adage Capital Management, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

SOURCE OF FUNDS

AF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

5,091,231

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

5,091,231

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

5,091,231

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

7.90%

14

TYPE OF REPORTING PERSON

PN, IA

         

 

CUSIP No. 38000Q102SCHEDULE 13DPage 3 of 11 Pages

 

 

1

NAME OF REPORTING PERSON

Robert Atchinson

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

SOURCE OF FUNDS

AF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
6

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

5,091,231

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

5,091,231

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

5,091,231

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

7.90%

14

TYPE OF REPORTING PERSON

IN; HC

         

 

CUSIP No. 38000Q102SCHEDULE 13DPage 4 of 11 Pages

 

1

NAME OF REPORTING PERSON

Phillip Gross

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

SOURCE OF FUNDS

AF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
6

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

5,091,231

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

5,091,231

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

5,091,231

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

7.90%

14

TYPE OF REPORTING PERSON

IN; HC

         

 

CUSIP No. 38000Q102SCHEDULE 13DPage 5 of 11 Pages

  

Item 1. SECURITY AND ISSUER
   
  This statement on Schedule 13D (the "Schedule 13D") relates to the common stock, $0.001 par value per share (the "Common Stock"), of GlycoMimetics, Inc., a Delaware corporation (the "Issuer"). The Issuer's principal executive offices are located at 9708 Medical Center Drive, Rockville, MD 20850.

 

Item 2. IDENTITY AND BACKGROUND
   
(a) This statement is filed by:

 

  (i) Adage Capital Management, L.P., a Delaware limited partnership ("ACM"), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership ("ACP"), with respect to the shares of Common Stock directly held by ACP;
     
  (ii) Robert Atchinson ("Mr. Atchinson"), as (i) managing member of Adage Capital Advisors, L.L.C., a Delaware limited liability company ("ACA"), managing member of Adage Capital Partners GP, L.L.C., a Delaware limited liability company ("ACPGP"), general partner of ACP and (ii) managing member of Adage Capital Partners LLC, a Delaware limited liability company ("ACPLLC"), general partner of ACM, with respect to the shares of Common Stock directly held by ACP; and
     
  (iii) Phillip Gross ("Mr. Gross"), as (i) managing member of ACA, managing member of ACPGP and (ii) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock directly held by ACP.

 

  The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
   
  The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
   
(b) The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
   
(c) The principal business of ACM is to serve as investment manager to ACP. The principal business of each of Messrs. Atchinson and Gross is the management of investments in securities.

 

CUSIP No. 38000Q102SCHEDULE 13DPage 6 of 11 Pages

  

(d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
   
(e) ACM consented to an Order Instituting Cease-And-Desist Proceedings ("Order") by the Securities and Exchange Commission ("SEC").  The Order was issued on September 25, 2024.  In the Order, the SEC found violations (i.e., late filings) of Sections 13(d) and 16(a) of the Act and Rules 13d-1 and 16a-3 promulgated thereunder in 2020 and 2021 with respect to two separate issuers of securities held by ACP. Without admitting or denying any wrongdoing, ACM agreed to cease and desist from committing or causing any violations or future violations of Sections 13(d) and 16(a) of the Exchange Act and Rules 13d-1 and 16a-3 thereunder, and paid a civil money penalty in the amount of $200,000. The Order notes that there is no state of mind requirement for violations of Section 16(a) and 13(d) of the Act and the rules thereunder and that the failure to timely file a required report, even if inadvertent, constitutes a violation. The Order further notes that, in determining to accept the offer, the SEC considered certain remedial acts undertaken by ACM and cooperation afforded to SEC staff. ACM has since implemented additional policies and procedures to protect against future inadvertent Section 13 and Section 16 violations.  Except as described above, during the last five years no Reporting Person was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
   
  Schedule A attached hereto sets forth the information required by Instruction C of the instructions to Schedule 13D.
   
(f) ACM is a Delaware limited partnership.  Messrs. Atchinson and Gross are citizens of the United States.

 

Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
   
  Funds for the purchase of the 5,091,231 shares of Common Stock to which this Schedule 13D relates were derived from working capital of ACP made in the ordinary course of business. A total of approximately $1,992,569, inclusive of commissions, was paid to acquire the 5,091,231 shares of Common Stock reported herein.  

 

CUSIP No. 38000Q102SCHEDULE 13DPage 7 of 11 Pages

  

Item 4. PURPOSE OF TRANSACTION
   
  The Reporting Persons acquired the shares of Common Stock to which this Schedule 13D relates for investment purposes in the ordinary course of business, and not with the purpose nor with the effect of changing or influencing the control or management of the Issuer.  The Reporting Persons acquired the shares of Common Stock pursuant to investment strategies, including merger arbitrage and event driven strategies, because they believed that the shares of Common Stock reported herein, when purchased, represented an attractive investment opportunity. Accordingly, the Reporting Persons may not be eligible to report this position on a Schedule 13G. See Colish, Faith (No-Act., Available March 24, 1980). On October 29, 2024, the Issuer filed a Current Report on Form 8-K disclosing it had entered into an Agreement and Plan of Merger and Reorganization dated as of October 28, 2024 (the "Merger Agreement") with Gemini Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of the Issuer, Gemini Merger Sub II, LLC, a Delaware limited liability company and wholly-owned subsidiary of the Issuer and Crescent Biopharma, Inc., a Delaware corporation. The transactions contemplated by the Merger Agreement are hereinafter referred to as the "Proposed Transaction".
   

  Except as set forth herein, the Reporting Persons have no present plan or proposal that would relate to or result in any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule 13D. The Reporting Persons have not entered into any agreement with any third party to act together for the purpose of acquiring, holding, voting or disposing of the shares of Common Stock reported herein.  The Reporting Persons intend to review their investment in the Issuer on a continuing basis and may from time to time engage in discussions with management, the Board of Directors, other shareholders of the Issuer and other relevant parties, including representatives of any of the foregoing, concerning matters with respect to the Reporting Persons' investment in the shares of Common Stock, including, without limitation, the business, operations, governance, management, strategy and future plans of the Issuer. Depending on various factors, including, without limitation, the terms of the Proposed Transaction and any other offers or developments related thereto, the outcome of any discussions referenced above, the Issuer's financial position and strategic direction, actions taken by the Board of Directors, price levels of the shares of Common Stock, other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate, including, without limitation, purchasing additional shares of Common Stock or selling some or all of their shares of Common Stock, engaging in short selling of or any hedging or similar transactions with respect to the shares of Common Stock and/or otherwise changing their intention with respect to any and all matters referred to in Item 4 of Schedule 13D.  The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect to their investment in the shares of Common Stock.  

 

CUSIP No. 38000Q102SCHEDULE 13DPage 8 of 11 Pages

  

Item 5. INTEREST IN SECURITIES OF THE ISSUER
   
(a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by each of the Reporting Persons.  The percentages used in this Schedule 13D are calculated based upon 64,483,958 shares of Common Stock outstanding on September 30, 2024, as reported in Exhibit 2.1 to the Company's Current Report on Form 8-K, filed with the SEC on October 29, 2024.
(b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
   
(c) The transactions in the shares of Common Stock within the past sixty (60) days by the Reporting Persons, which were all in the open market, are set forth in Schedule B, and are incorporated herein by reference.
   
(d) No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, such shares of Common Stock.
   
(e) Not applicable.

 

Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
   
  Other than the Joint Filing Agreement attached as Exhibit 99.1 hereto, there are no contracts, arrangements, understandings or similar relationships with respect to the securities of the Issuer between any of the Reporting Persons or Instruction C Persons and any other person or entity.

 

Item 7. MATERIAL TO BE FILED AS EXHIBITS
   
Exhibit 99.1: Joint Filing Agreement Statement as required by Rule 13d-1(k)(1) under the Act.

 

 

CUSIP No. 38000Q102SCHEDULE 13DPage 9 of 11 Pages

 

SIGNATURES

After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATE: November 4, 2024

 

ADAGE CAPITAL MANAGEMENT, L.P.  
By: Adage Capital Partners LLC,  
its general partner  
   
/s/ Robert Atchinson  
Name:  Robert Atchinson  
Title: Managing Member  
   
/s/ Robert Atchinson  
ROBERT ATCHINSON, individually  
   
/s/ Phillip Gross  
PHILLIP GROSS, individually  

 

CUSIP No. 38000Q102SCHEDULE 13DPage 10 of 11 Pages

SCHEDULE A

 

GENERAL PARTNERS, CONTROL PERSONS, DIRECTORS AND EXECUTIVE OFFICERS OF CERTAIN REPORTING PERSONS

 

The following sets forth the name, position, address, principal occupation and citizenship of each general partner, control person, director and/or executive officer of the applicable Reporting Persons (the "Instruction C Persons"). To the best of the Reporting Persons’ knowledge, (i) none of the Instruction C Persons during the last five years has been convicted in a criminal proceeding (excluding traffic violations or other similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws and (ii) none of the Instruction C Persons owns any shares of Common Stock or is party to any contract or agreement as would require disclosure in this Schedule 13D, except to the extent such Instruction C Person is a Reporting Person in which case such Instruction C Person’s beneficial ownership is as set forth in Item 5 of the Schedule 13D.

 

REPORTING PERSON: ADAGE CAPITAL MANAGEMENT, L.P. ("ACM")

 

Adage Capital Partners L.L.C. ("ACPLLC") serves as the general partner of ACM. Its business address is c/o Adage Capital Management, L.P., 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. Its principal occupation is serving as the general partner of ACM. ACPLLC is a Delaware limited liability company.

 

Adage Capital Advisors, L.L.C. ("ACA”), serves as the managing member of ACPLLC. The business address of ACA is c/o Adage Capital Management, L.P., 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. The principal occupation of ACA is serving as managing member of ACPLLC. ACA is a Delaware limited liability company.

 

Messrs. Atchinson and Gross serve as the managing members of ACA. Messrs. Atchinson and Gross are Reporting Persons.

 

CUSIP No. 38000Q102SCHEDULE 13DPage 11 of 11 Pages

 

Schedule B

 

This Schedule sets forth information with respect to each purchase and sale of shares of Common Stock which were effectuated by the Reporting Persons within the past sixty (60) days. All transactions were effectuated in the open market through a broker. The price reported in the column Price Per Share ($) is a weighted average price if a price range is indicated in the column Price Range ($). These shares of Common Stock were purchased or sold in multiple transactions at prices between the price ranges below. The Reporting Persons will undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares of Common Stock purchased or sold at each separate price.

 

Trade Date Shares Purchased (Sold) Price Per Share ($)* Price Range ($)*
10/29/2024 1,591,231 0.3682 0.3348-0.38
10/29/2024 2,500,000 0.3824 0.372-0.4
10/31/2024 379,380 0.4  —
10/31/2024 51,671 0.394 0.3869-0.4
11/1/2024 568,949 0.4 0.3978-0.4
       

*       Excluding commissions.

 

 

Get the next $GLYC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GLYC

DatePrice TargetRatingAnalyst
3/21/2025Overweight
Cantor Fitzgerald
7/26/2024Buy → Hold
TD Cowen
12/22/2023$12.00Overweight
CapitalOne
11/12/2021$3.00 → $4.00Hold → Buy
Jefferies
More analyst ratings

$GLYC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

    WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 9:10 am ET. A live webcast of the presentation will be available at https://wsw.com/webcast/cowen177/cresc/2175696. An archived recording will be available for 90 days following the event. In October 2024, Crescent entered into an acquisition agreement with Rockville, Maryland-based GlycoMimetics, Inc. (NASDAQ:GLYC). Following

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

    Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT. A live webcast of the presentation will be available at https://wsw.c

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

    GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024. ASH Annual Meeting abstracts may be accessed online at www.hematology.org. Details of GlycoMimetics presentations are as follows (all times PT): Publication Number: 733 Type: Oral Title: Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Tria

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GLYC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GLYC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$GLYC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GLYC
SEC Filings

See more

$GLYC
Leadership Updates

Live Leadership Updates

See more
  • GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

    GlycoMimetics, Inc. (NASDAQ:GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO). Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts. "We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as w

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations

    GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations. "Dr. Tiwari brings over 25 years of diverse CMC experience. He has contributed to more than 30 regulatory submissions and 15 commercial product launches throughout his career. As we continue to move uproleselan forward, Deepak's breadth of experience and leadership is a valuable addition to GlycoMimetics," commented Harout Semerjian, GlycoMimetics' Chief Executive Officer. Dr. Tiwari joins the Company from Rafael Pharmaceuticals where he was Vice President and Head of CMC Operations working on development of devimistat in multiple indications including p

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial Officer

    GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Bruce Johnson has joined its executive leadership team as Senior Vice President and Chief Commercial Officer. "Bruce brings to GlycoMimetics a wealth of oncology / hematology expertise particularly in leading commercial and development activities across multiple launches. He shepherded two AML drugs, Midostaurin and Venetoclax, through late-stage development and approval, uniquely qualifying him to lead the commercialization efforts of our lead asset, uproleselan, should the results of our ongoing Phase 3 registrational AML trial prove positive. His near-term focus will be to develop a commercialization strategy for uproleselan, accele

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GLYC
Financials

Live finance-specific insights

See more
  • GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

    Following closing, the combined company will advance Crescent's portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent's lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected to have preliminary proof of concept data in 2H26 Crescent pipeline also includes two novel antibody-drug conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003 Concurrent financing of approximately $200 million anticipated to fund operations through 2027 Companies to hold a conference call on Tuesday October 29, at 8:00am EDT GlycoMim

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

    Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm in this subgroup Adverse events for uproleselan were consistent with known side effect profiles of chemotherapy used in the study Advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for Phase 2/3

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

    Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy used in the study Comprehensive data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results for presentation at an upcoming medical meeting National Cancer Institute (NCI) Phase 2/3 study in newly diagnosed AML patients remains ongoing Conference call and webcast to be hosted today, May 6, 2024, at 8:30 a.m. ET. GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GLYC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more

$GLYC
Insider purchases explained

Analytical look into recent insider purchases

See more
  • What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care